Eliksa develops regenerative ophthalmic medicines for the ocular complications of Epidermolysis Bullosa, an ultra‑rare genetic disorder with no approved therapies. Its investigational product, ELK‑003, is an acellular eye‑drop formulation containing proprietary biological components processed in a cGMP‑compliant facility to ensure consistent therapeutic activity and safety. The topical drops deliver regenerative factors directly to the eye surface, aiming to promote healing and preserve vision for affected patients.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with Epidermolysis Bullosa, an ultra‑rare genetic disorder, often develop severe ocular complications for which there are no approved therapies, leading to progressive vision loss and limited quality of life.
Solution
Eliksa develops regenerative ophthalmic medicines that address the unmet need in EB‑related eye disease. Their investigational product, ELK‑003, is an acellular eye‑drop formulation derived from specialized biological components processed in a cGMP‑compliant facility to retain therapeutic activity. The formulation is designed to be applied topically, delivering regenerative factors directly to the ocular surface to promote healing and preserve vision. By leveraging proprietary processing and sterilization methods, Eliksa ensures batch‑to‑batch consistency and safety while maintaining the biological potency required for therapeutic effect. The company advances the product through clinical trials to establish efficacy and safety for children and adults affected by EB ocular manifestations.
Target Audience
Primary customers are ophthalmologists, dermatologists, and specialty clinics that treat patients with Epidermolysis Bullosa, as well as research institutions and pharmaceutical partners pursuing rare‑disease therapies.
Features
- Acellular eye‑drop formulation containing regenerative biological components
- cGMP‑manufactured with validated processing and sterilization to ensure consistent activity
- Topical delivery enables non‑invasive administration directly to the ocular surface
- Designed specifically for the ocular complications of Epidermolysis Bullosa
- Proprietary technology preserves vital biological activity while eliminating cellular material